About OliX Pharmaceuticals
OliX Pharmaceuticals is a publicly listed company based in Suwon (South Korea) founded in 2010. RNAi therapeutics are developed for dermal, ophthalmic, and pulmonary diseases. It operates in the Healthcare and Technology sectors. The company has 69 employees. Its website olixpharma.com draws about 34 thousand monthly visits. Its focus areas include Life Sciences, Genomics, Enabling Technologies and Technology Platforms.
Company details
Developer of RNAi therapeutics for dermal, ophthalmic, and pulmonary diseases. Its drug pipeline includes OLX101 for the treatment of Skin Scar (licensed out to Huge Inc.), OLX201 for the treatment of Lung fibrosis, OLX301 for the treatment of Wet AMDRetinal Fibrosis, OLX701 for liver fibrosis. Other products include OLX102 for skin whitening and OLX105 to get rid of wrinkles. The companys technology is based on three types of RNA: Small interfering RNA (siRNA), Asymmetric siRNA (siRNA), and Cell-penetrating asymmetric siRNA (cp-siRNA).
- Headquarters Suwon, South Korea
- Employees 69
- Stage Public
- SectorsHealthcareTechnology
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Phone•••• ••••
- Website olixpharma.com
- Social LinkedIn X Facebook YouTube
- Legal Name Olix Pharmaceuticals, Inc.
- Annual Revenue$10.16 M (USD)158.35as on Dec 31, 2025
- Net Profit-$10.9 M (USD)61.28as on Dec 31, 2025
- EBITDA-$19.06 M (USD)2.73as on Dec 31, 2025
- Latest Funding Round$72.74M (USD), Post-IPO
Jun 2026
- InvestorsBOLD
& 1 more
- Employee Count69
Apps and channels of OliX Pharmaceuticals
its YouTube channel 올릭스 OliX Pharmaceuticals, Inc. has 1.06K subscribers and 17 videos.
Videos from OliX Pharmaceuticals
The most watched videos on OliX Pharmaceuticals's YouTube channel, 올릭스 OliX Pharmaceuticals, Inc. (1.06K subscribers). Click a video to play it here.
More on 올릭스 OliX Pharmaceuticals, Inc..
Funding Insights of OliX Pharmaceuticals
- Total Rounds 1
- Last Round Post-IPO — $72.74M
- First Round $72.74M
(Jun 2026)
- Investors Count 2
All 1 funding rounds of OliX Pharmaceuticals with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2026 | $72.74M | Post-IPO | – | – |
2 investors in total: 2 institutional.
Investors in OliX Pharmaceuticals
OliX Pharmaceuticals has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include BOLD and Weiss Asset Management.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
| lorealboldventures.com | ||||
| weissasset.com |
Investor details for OliX Pharmaceuticals
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of OliX Pharmaceuticals
14 people are tracked at OliX Pharmaceuticals (7 in leadership, 7 in team); the tracked headcount is 69.
| Name | Role | Group |
|---|---|---|
Toni Bransford | Senior Vice President, Head Of Clinical Development | Leadership |
Lee Dong-gi | CEO | Leadership |
Baek Yeong-hye | Managing Director, IP & Legal General | Leadership |
Dongwon Shin | Vice President | Leadership |
Debasis Patra | Vice President, Head of CMC | Leadership |
Shinyoung Park | SVP & General Manager of Development | Leadership |
Seonwoo Hong Ph.D. | VP & Head of Research | Leadership |
Jisun Lee | Team Leader / Legal Counsel | Team |
Namho Kim | Sr Principal Research Scientist | Team |
Duck-kyu Kim | Researcher | Team |
연우 김 | Scientist | Team |
Jiyoung Lee | Senior Scientist | Team |
W. Padraig Madden | Research Associate III - Analytics | Team |
Young Jun Lee | Human Resources Team Lead | Team |
Complete people profiles for OliX Pharmaceuticals
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of OliX Pharmaceuticals
OliX Pharmaceuticals is a publicly listed company on the KRX with ticker symbol 226950 in South Korea, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date20 Jul 2018
- Listed onKRX: 226950
- Listed entityOliX Pharmaceuticals, Inc.
- Exchange sectorHealth technology
- ISINKR7226950004
- Share price91,300.00 KRW (+0.33% on the day) · 2026-10-14
- Market capitalisation2,081,611,982,346.00 KRW
- EPS (diluted, trailing year)-603.19 KRW
- Volume (last session)330,261
Financials of OliX Pharmaceuticals
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 14.67B KRW | -15.74B KRW | -27.52B KRW |
| 2024 | 5.68B KRW | -40.66B KRW | -28.29B KRW |
| 2023 | 17.06B KRW | -19.10B KRW | -15.54B KRW |
| 2022 | 9.32B KRW | -19.50B KRW | -20.40B KRW |
| 2021 | 3.67B KRW | -29.71B KRW | -22.61B KRW |
Detailed financial statements for OliX Pharmaceuticals
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of OliX Pharmaceuticals
3 dated milestones of OliX Pharmaceuticals across 16 years, from founding to its latest funding, stage changes and deals.
- Founded OliX Pharmaceuticals is founded.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round of $72.7M.
Web traffic of OliX Pharmaceuticals
The website of OliX Pharmaceuticals (olixpharma.com) receives about 33.6K visits a month and ranks #526,441 among all websites worldwide, #540 in Biotechnology and Pharmaceuticals.
- Monthly visits33.6K
▲ 4.4% vs previous month
- Unique visitors4.3K
per month
- Global rank#526,441
among all websites
- Category rank#540
Health · Biotechnology and Pharmaceuticals
- Bounce rate18%
- Pages per visit17.2
- Average visit34 min 58 sec
- DevicesDesktop 81% · Mobile 19%
Websites whose visitors overlap most with OliX Pharmaceuticals. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| hitnews.co.kr | 100% | #146,502 | View details | ||
medipana.com | medipana.com | 98% | #266,587 | – | |
| medisobizanews.com | 97% | #283,693 | View details | ||
| biotimes.co.kr | 97% | #456,742 | View details | ||
docdocdoc.co.kr | docdocdoc.co.kr | 97% | #141,726 | – | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 8 similar websites and full traffic analytics for OliX Pharmaceuticals
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 8 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Olix Pharmaceuticals
Complete news archive for OliX Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about OliX Pharmaceuticals
OliX Pharmaceuticals was founded in 2010 and raised its 1st funding round 16 years after it was founded.
OliX Pharmaceuticals is headquartered in Suwon, South Korea. It is registered at Suwon, Gyeonggi, South Korea.
OliX Pharmaceuticals has 69 employees.
Annual revenue of OliX Pharmaceuticals is $10.16M as on Dec 31, 2025.
Developer of RNAi therapeutics for dermal, ophthalmic, and pulmonary diseases. Its drug pipeline includes OLX101 for the treatment of Skin Scar (licensed out to Huge Inc.), OLX201 for the treatment of Lung fibrosis, OLX301 for the treatment of Wet AMDRetinal Fibrosis, OLX701 for liver fibrosis. Other products include OLX102 for skin whitening and OLX105 to get rid of wrinkles. The companys technology is based on three types of RNA: Small interfering RNA (siRNA), Asymmetric siRNA (siRNA), and Cell-penetrating asymmetric siRNA (cp-siRNA).
Yes, OliX Pharmaceuticals is publicly traded on KRX under the ticker symbol 226950.
OliX Pharmaceuticals has 2 investors. Key investors include BOLD, and Weiss Asset Management.